Thiopurines Boost Lymphoma Risk Three-Fold, But Wait

According to a study reported at the annual meeting of the American College of Gastroenterology, the continuous use of thiopurines in patients with ulcerative colitis (UC) boosts the risk of developing non-Hodgkin's lymphoma three-fold.

However, while that may sound dramatic, the absolute risk for lymphoma remains low enough that experts don't believe these results should warrant patients discontinuing medication, especially if they derive a lot of benefit from it.

This retrospective cohort study included data from 36,826 patients with UC treated in the Southeast Louisiana Veterans Health Care System in a 10-year span. Patients were divvied into one of three groups:

  1. Continuous users of thiopurines (2 percent)
  2. Discontinuous users of thiopurines (11 percent)
  3. Nonusers of thiopurines (87 percent)

After a median follow-up of six years, investigators determined the incidence rate of lymphoma to be 2.8 cases per 1,000 patient-years in those using thiopurines continuously. That rate is compared to 0.7 and 0.8 per 1,000 patient-years for the other two groups respectively. These rates worked out to a hazard ratio of 3.2 for continuous users compared to the other groups.

These data are fairly consistent with the existing data on the use of thiopurines and lymphoma. The findings do not add anything new to the discussion, but they do add weight to the ongoing notion that immunosuppressive drugs can increase one's risk of developing lymphoma.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap